State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 8,356,408 shares of Altimmune Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 8,356,408 shares of Altimmune Inc. common stock, representing 4.3% of the class.
  • Shared voting power: State Street disclosed shared voting power over 8,164,809 shares, with zero sole voting power.
  • Shared dispositive power: The filing reported shared dispositive power over 8,356,408 shares, with zero sole dispositive power.
  • Reporting entity type: State Street Corporation identified itself as a parent holding company (type "HC") organized in Massachusetts.
  • Subsidiaries involved: The filing identified three subsidiaries that acquired the securities: SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser (IA).
  • Event date: The date of the event requiring the filing was September 30, 2026.

State Street Corporation Discloses Passive Stake in Altimmune as of September 30, 2026

State Street Corporation, headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing a 4.3% beneficial ownership position in Altimmune Inc. (CUSIP 02155H200), a company whose principal executive offices are located at 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878. The filing was signed by Alok Maheshwary, Senior Vice President, and dated November 9, 2026.

According to the filing, State Street holds shared voting power over 8,164,809 shares and shared dispositive power over 8,356,408 shares. The filing reports zero sole voting power and zero sole dispositive power. The aggregate amount beneficially owned is listed as 8,356,408 shares. The filing noted in Item 5 that this represents ownership of 5 percent or less of the class.

The filing identified three subsidiaries through which the securities were acquired: SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, all classified as investment advisers. Per the certification in Item 10, the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation filed a Schedule 13G disclosing beneficial ownership of 8,356,408 shares, or 4.3%, of Altimmune Inc. common stock as of September 30, 2026, held through three investment adviser subsidiaries with shared but no sole voting or dispositive power.